|
US7901693B2
(en)
|
1998-09-30 |
2011-03-08 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7115272B1
(en)
|
1998-09-30 |
2006-10-03 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7329410B1
(en)
|
1998-09-30 |
2008-02-12 |
Corixa Corporation |
Compositions and method for WT1 specific immunotherapy
|
|
US7144581B2
(en)
|
2000-10-09 |
2006-12-05 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7655249B2
(en)
|
1998-09-30 |
2010-02-02 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7063854B1
(en)
|
1998-09-30 |
2006-06-20 |
Corixa Corporation |
Composition and methods for WTI specific immunotherapy
|
|
US7029847B2
(en)
|
2000-05-16 |
2006-04-18 |
Massachusetts Institute Of Technology |
Methods and compositions for interaction trap assays
|
|
WO2001088197A2
(en)
*
|
2000-05-16 |
2001-11-22 |
Massachusetts Institute Of Technology |
Methods and compositions for interaction trap assays
|
|
AU2002225187A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Sangamo Biosciences, Inc. |
Zinc finger polypeptides and their use
|
|
CN1289522C
(zh)
*
|
2001-08-17 |
2006-12-13 |
图尔金株式会社 |
锌指结构域文库
|
|
US7553494B2
(en)
|
2001-08-24 |
2009-06-30 |
Corixa Corporation |
WT1 fusion proteins
|
|
WO2003048345A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Toolgen, Inc. |
Phenotypic screen of chimeric proteins
|
|
US8799501B2
(en)
*
|
2002-04-30 |
2014-08-05 |
Hewlett-Packard Development Company, L. P. |
System and method for anonymously sharing and scoring information pointers, within a system for harvesting community knowledge
|
|
JP2006513694A
(ja)
*
|
2002-06-11 |
2006-04-27 |
ザ スクリップス リサーチ インスティテュート |
人工転写因子
|
|
AU2003260973A1
(en)
*
|
2002-09-05 |
2004-03-29 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
|
KR100766952B1
(ko)
*
|
2002-12-09 |
2007-10-17 |
주식회사 툴젠 |
조절성 징크 핑거 단백질
|
|
CN1836048A
(zh)
*
|
2003-06-10 |
2006-09-20 |
图尔金株式会社 |
可转导的dna结合蛋白
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
KR20060039019A
(ko)
|
2003-08-08 |
2006-05-04 |
상가모 바이오사이언스 인코포레이티드 |
표적화된 절단과 재조합을 위한 방법 및 그 조성물
|
|
EP1678315B1
(de)
|
2003-09-19 |
2011-08-03 |
Sangamo BioSciences, Inc. |
Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
|
|
US20070042378A1
(en)
*
|
2003-12-23 |
2007-02-22 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
|
ES2315859T3
(es)
*
|
2004-04-08 |
2009-04-01 |
Sangamo Biosciences, Inc. |
Metodos y composiciones para tratar afecciones neuropaticas y neurodegenerativas.
|
|
WO2005116060A1
(en)
|
2004-05-25 |
2005-12-08 |
Toolgen, Inc. |
Polypeptide increasing the monoclonal antibody production, nucleic acid encoding same and use thereof
|
|
KR20070060115A
(ko)
|
2004-09-16 |
2007-06-12 |
상가모 바이오사이언스 인코포레이티드 |
단백질 생산을 위한 조성물 및 방법
|
|
US20090263900A1
(en)
|
2008-04-14 |
2009-10-22 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
CA2615532C
(en)
|
2005-07-26 |
2016-06-28 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
|
CA2651499C
(en)
|
2006-05-25 |
2015-06-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for ccr-5 gene inactivation
|
|
JP5266210B2
(ja)
|
2006-05-25 |
2013-08-21 |
サンガモ バイオサイエンシズ インコーポレイテッド |
改変開裂ハーフドメイン
|
|
US9428756B2
(en)
|
2006-08-11 |
2016-08-30 |
Dow Agrosciences Llc |
Zinc finger nuclease-mediated homologous recombination
|
|
KR100812110B1
(ko)
*
|
2006-10-24 |
2008-03-12 |
한국과학기술원 |
징크 핑거 단백질과 원핵 생물의 전사 인자를 포함하는인공 전사 인자의 제조 및 이의 이용
|
|
WO2008060510A2
(en)
*
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
PT2415872T
(pt)
|
2006-12-14 |
2016-07-07 |
Sangamo Biosciences Inc |
Proteínas com dedos de zinco não canónicas optimizadas
|
|
EP2137310B1
(de)
|
2007-04-26 |
2010-11-24 |
Sangamo BioSciences, Inc. |
Gezielte integration in die ppp1r12c-position
|
|
CN101883850B
(zh)
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
用于失活α-1,6岩藻糖基转移酶(FUT8)基因表达的方法和组合物
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
US8399218B2
(en)
|
2007-09-27 |
2013-03-19 |
Dow Agrosciences, Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
AU2008305567B2
(en)
|
2007-09-27 |
2014-04-10 |
Sangamo Therapeutics, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
EP2205752B1
(de)
|
2007-10-25 |
2016-08-10 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen für gezielte integration
|
|
US10316288B2
(en)
|
2008-04-30 |
2019-06-11 |
Sanbio, Inc. |
Neural regenerating cells with alterations in DNA methylation
|
|
EP2297318B1
(de)
|
2008-05-28 |
2018-05-23 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zum verknüpfen von dna-bindungsdomänen und spaltungsdomänen
|
|
EP2910568B1
(de)
|
2008-06-10 |
2018-08-22 |
Sangamo Therapeutics, Inc. |
Verfahren und Zusammensetzungen zur Erzeugung von BAX- und BAK-Mangel-Zelllinien
|
|
WO2010021692A1
(en)
|
2008-08-22 |
2010-02-25 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
KR101673566B1
(ko)
|
2008-10-29 |
2016-11-07 |
상가모 바이오사이언스 인코포레이티드 |
글루타민 신테타제 유전자 발현을 불활성화시키기 위한 방법 및 조성물
|
|
WO2010065123A1
(en)
|
2008-12-04 |
2010-06-10 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
SI2370575T1
(en)
|
2008-12-17 |
2018-07-31 |
Dow Agrosciences, Llc |
Targeted integration in the Zp15 locus
|
|
AU2010211057B2
(en)
|
2009-02-04 |
2014-12-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating neuropathies
|
|
US8871905B2
(en)
|
2009-03-20 |
2014-10-28 |
Sangamo Biosciences, Inc. |
Modification of CXCR4 using engineered zinc finger proteins
|
|
WO2010117464A1
(en)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
EP2449135B1
(de)
|
2009-06-30 |
2016-01-06 |
Sangamo BioSciences, Inc. |
Schnelles screening biologisch aktiver nukleasen und isolation nukleasemodifizierter zellen
|
|
JP5866283B2
(ja)
|
2009-07-28 |
2016-02-17 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
トリヌクレオチド反復疾患を治療するための方法および組成物
|
|
NZ598457A
(en)
|
2009-08-03 |
2014-06-27 |
Recombinetics Inc |
Methods and compositions for targeted gene modification
|
|
KR20170125406A
(ko)
|
2009-08-11 |
2017-11-14 |
상가모 테라퓨틱스, 인코포레이티드 |
표적화 변형에 대한 동형접합성 유기체
|
|
EP2722392B1
(de)
|
2009-10-22 |
2017-11-22 |
Dow AgroSciences LLC |
Manipulierte Zinkfingerproteine zur Abzielung auf in Fettsäure-Biosynthese involvierte Pflanzengene
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
EA031322B1
(ru)
|
2010-01-22 |
2018-12-28 |
Дау Агросайенсиз Ллс |
Клетка или клеточная линия для экспрессии экзогенных нуклеотидных последовательностей и применение клетки или клеточной линии
|
|
FR2955480B1
(fr)
|
2010-01-26 |
2012-01-06 |
Christian Choux |
Dispositif d'osteosynthese de la paroi thoracique
|
|
DK2534173T3
(da)
|
2010-02-08 |
2019-10-14 |
Sangamo Therapeutics Inc |
Manipulerede spaltnings-halvdomæner
|
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US8771985B2
(en)
|
2010-04-26 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using zinc-finger nucleases
|
|
EP3636766A1
(de)
|
2010-05-03 |
2020-04-15 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur verknüpfung von zinkfingermodulen
|
|
WO2011146121A1
(en)
|
2010-05-17 |
2011-11-24 |
Sangamo Biosciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
WO2012012667A2
(en)
|
2010-07-21 |
2012-01-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a hla locus
|
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
ES2562421T3
(es)
|
2010-10-12 |
2016-03-04 |
The Children's Hospital Of Philadelphia |
Métodos y composiciones para tratar la hemofilia B
|
|
US9267123B2
(en)
*
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
US20140186340A1
(en)
|
2011-04-08 |
2014-07-03 |
Gilead Biologics, Inc. |
Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
|
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
SG10201811736QA
(en)
|
2011-09-21 |
2019-02-27 |
Sangamo Therapeutics Inc |
Methods and compositions for regulation of transgene expression
|
|
IN2014CN02586A
(de)
*
|
2011-10-11 |
2015-08-07 |
Aliophtha Ag |
|
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
JP6144691B2
(ja)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス, インコーポレイテッド |
修飾されたdna結合タンパク質およびその使用
|
|
EP2806881A1
(de)
|
2012-01-27 |
2014-12-03 |
SanBio, Inc. |
Verfahren und zusammensetzungen zur modulation der angiogenese und vaskulogenese
|
|
CN104204225A
(zh)
|
2012-02-29 |
2014-12-10 |
桑格摩生物科学股份有限公司 |
治疗亨廷顿氏病的方法和组合物
|
|
CN102634535B
(zh)
*
|
2012-04-12 |
2014-11-26 |
西北农林科技大学 |
一种基于锌指蛋白插入载体的随机锌指蛋白库的构建方法
|
|
MX369788B
(es)
|
2012-05-02 |
2019-11-21 |
Dow Agrosciences Llc |
Modificacion dirigida de deshidrogenasa de malato.
|
|
KR102116153B1
(ko)
|
2012-05-07 |
2020-05-27 |
상가모 테라퓨틱스, 인코포레이티드 |
도입유전자의 뉴클레아제-매개 표적화된 통합을 위한 방법 및 조성물
|
|
ES2697912T3
(es)
|
2012-07-11 |
2019-01-29 |
Sangamo Therapeutics Inc |
Métodos y composiciones para el tratamiento de enfermedades monogénicas
|
|
JP6329537B2
(ja)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
生物学的薬剤の送達のための方法および組成物
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
US9650648B2
(en)
|
2012-08-29 |
2017-05-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
|
US9914930B2
(en)
|
2012-09-07 |
2018-03-13 |
Dow Agrosciences Llc |
FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
US9597357B2
(en)
|
2012-10-10 |
2017-03-21 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
BR102013032200A2
(pt)
|
2012-12-13 |
2015-11-24 |
Dow Agrosciences Llc |
direcionamento preciso de um gene para um locus específico em milho
|
|
CA2901676C
(en)
|
2013-02-25 |
2023-08-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
HK1218232A1
(zh)
|
2013-03-21 |
2017-02-10 |
桑格摩生物科学股份有限公司 |
使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因
|
|
KR102223568B1
(ko)
|
2013-04-05 |
2021-03-04 |
다우 아그로사이언시즈 엘엘씨 |
식물의 게놈 내의 외인성 서열의 통합을 위한 방법 및 조성물
|
|
HK1223401A1
(zh)
|
2013-05-15 |
2017-07-28 |
桑格摩生物科学股份有限公司 |
用於治疗遗传病状的方法和组合物
|
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
EP3058072B1
(de)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CA2928666C
(en)
|
2013-11-04 |
2023-05-23 |
Dow Agrosciences Llc |
Optimal maize loci for targeted genome modification
|
|
JP6634022B2
(ja)
|
2013-11-04 |
2020-01-22 |
ダウ アグロサイエンシィズ エルエルシー |
最適なダイズ遺伝子座
|
|
UA120503C2
(uk)
|
2013-11-04 |
2019-12-26 |
Дау Агросайєнсиз Елелсі |
Спосіб одержання трансгенної клітини рослини кукурудзи
|
|
BR102014027466B1
(pt)
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, método para produzir uma célula vegetal transgênica e usos de uma planta de soja, parte de planta de soja ou célula de planta de soja transgênica
|
|
WO2015070212A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
PT3068881T
(pt)
|
2013-11-13 |
2019-05-31 |
Childrens Medical Center |
Regulação da expressão de genes mediada por nucleases
|
|
CA2931637C
(en)
|
2013-12-09 |
2023-10-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating hemophilia
|
|
EP3110454B1
(de)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur nukleasevermittelten gezielten integration
|
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
EP3139966B1
(de)
|
2014-05-08 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur verwendung bei der behandlung der huntington-krankheit
|
|
EP3142707A4
(de)
|
2014-05-13 |
2018-02-21 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur vorbeugung oder behandlung einer krankheit
|
|
EP3152319A4
(de)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur nukleasekonstruktion
|
|
EP3166964A1
(de)
|
2014-07-08 |
2017-05-17 |
Vib Vzw |
Mittel und verfahren zur steigerung des pflanzenertrags
|
|
EP4335926A3
(de)
|
2014-07-14 |
2024-06-12 |
Washington State University |
Nanos-knockout zur abladierung von keimbahnzellen
|
|
WO2016011381A1
(en)
|
2014-07-18 |
2016-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
CN106795488B
(zh)
|
2014-09-16 |
2021-03-30 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
EP3247366A4
(de)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur identifizierung hochspezifischer nukleasen
|
|
CA2981077A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
IL284707B2
(en)
|
2015-05-12 |
2024-01-01 |
Sangamo Therapeutics Inc |
Nuclease-mediated regulation of gene expression
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
BR112018002417A2
(pt)
|
2015-08-06 |
2018-09-18 |
Univ Missouri |
animal não humano ou descendente do mesmo ou uma célula de animal, animal suíno, descendente ou célula, célula, descendente, método de reprodução, população de animais, método para aumentar uma resistência de animal, molécula de ácido nucleico, ácido nucleico e ácido nucleico isolado
|
|
FI3352776T3
(fi)
|
2015-09-23 |
2025-07-08 |
Sangamo Therapeutics Inc |
Htt-repressoreita ja niiden käyttötapoja
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CN108778297B
(zh)
|
2015-12-18 |
2024-02-09 |
桑格摩生物治疗股份有限公司 |
T细胞受体的靶向破坏
|
|
SG11201805157TA
(en)
|
2015-12-18 |
2018-07-30 |
Sangamo Therapeutics Inc |
Targeted disruption of the mhc cell receptor
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
KR20180101442A
(ko)
|
2016-02-02 |
2018-09-12 |
상가모 테라퓨틱스, 인코포레이티드 |
Dna-결합 도메인 및 절단 도메인을 연결시키기 위한 조성물
|
|
EP3433362B1
(de)
|
2016-03-23 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur erhöhung der effizienz der geneditierung
|
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
MA53246A
(fr)
|
2016-07-27 |
2021-07-28 |
Univ Case Western Reserve |
Composés et procédés pour favoriser la myélinisation
|
|
JP7066126B2
(ja)
|
2016-08-09 |
2022-05-13 |
ブイアイビー ブイゼットダブリュ |
セルロースシンターゼ阻害剤および突然変異体植物
|
|
BR112019003100A2
(pt)
|
2016-08-24 |
2019-07-09 |
Sangamo Therapeutics, Inc. |
regulação da expressão gênica usando nucleases manipuladas
|
|
KR20220145913A
(ko)
|
2016-08-24 |
2022-10-31 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
|
EP3509645A4
(de)
|
2016-09-07 |
2020-06-17 |
Sangamo Therapeutics, Inc. |
Modulation von lebergenen
|
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
AU2017338846B2
(en)
|
2016-10-04 |
2020-09-24 |
Precision Biosciences, Inc. |
Co-stimulatory domains for use in genetically-modified cells
|
|
IL266047B2
(en)
|
2016-10-20 |
2025-02-01 |
Sangamo Therapeutics Inc |
Methods and compositions for the treatment of fabry disease
|
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
AU2017367722B2
(en)
|
2016-12-01 |
2024-02-01 |
Sangamo Therapeutics, Inc. |
Tau modulators and methods and compositions for delivery thereof
|
|
CN110249051A
(zh)
|
2016-12-08 |
2019-09-17 |
凯斯西储大学 |
增强功能性髓鞘产生的方法和组合物
|
|
KR20190140950A
(ko)
|
2017-04-20 |
2019-12-20 |
오레곤 헬스 앤드 사이언스 유니버시티 |
인간 유전자 교정
|
|
EP3619322A4
(de)
|
2017-05-03 |
2021-06-30 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur modifizierung eines mukoviszidose-transmembranleitungsregulator (cftr)-gens
|
|
WO2018208837A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
AU2018292526A1
(en)
|
2017-06-30 |
2020-01-16 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
|
AU2018313167A1
(en)
|
2017-08-08 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Chimeric antigen receptor mediated cell targeting
|
|
US20200239544A1
(en)
|
2017-10-03 |
2020-07-30 |
Precision Biosciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
MA50613A
(fr)
|
2017-10-03 |
2020-08-12 |
Editas Medicine Inc |
Molécules de liaison spécifique à l'hpv
|
|
WO2019089913A1
(en)
|
2017-11-01 |
2019-05-09 |
Precision Biosciences, Inc. |
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
|
|
BR112020008568A2
(pt)
|
2017-11-09 |
2020-10-06 |
Sangamo Therapeutics, Inc. |
modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
|
|
AU2018375192B2
(en)
|
2017-12-01 |
2023-11-09 |
Encoded Therapeutics, Inc. |
Engineered DNA binding proteins
|
|
WO2019125851A1
(en)
|
2017-12-18 |
2019-06-27 |
Syngenta Participations Ag |
Targeted insertion sites in the maize genome
|
|
WO2019143675A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
CA3088791A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
|
EP3740480B1
(de)
|
2018-01-17 |
2024-03-06 |
Vertex Pharmaceuticals Incorporated |
Dna-pk-hemmer
|
|
SG11202007440YA
(en)
|
2018-02-08 |
2020-09-29 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
JP7630280B2
(ja)
|
2018-04-05 |
2025-02-17 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現するt細胞、関連ポリヌクレオチド、および方法
|
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
JP7332622B2
(ja)
|
2018-04-18 |
2023-08-23 |
サンガモ セラピューティクス, インコーポレイテッド |
ハンチンチン(htt)の調節のためのジンクフィンガータンパク質組成物
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
KR102712986B1
(ko)
|
2018-08-23 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
|
US20210317430A1
(en)
|
2018-09-18 |
2021-10-14 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
|
CA3113449A1
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
EP3860618B1
(de)
|
2018-10-02 |
2026-02-04 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur behandlung von tauopathie
|
|
AU2019361129A1
(en)
|
2018-10-18 |
2021-05-20 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US20220090047A1
(en)
|
2018-12-21 |
2022-03-24 |
Precision Biosciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
CA3106693A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
US20200316116A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Method for the treatment of beta-thalassemia
|
|
CN113993999B
(zh)
|
2019-04-03 |
2022-11-22 |
精密生物科学公司 |
包含microRNA适应的shRNA(shRNAmiR)的遗传修饰的免疫细胞
|
|
WO2020206231A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
US12139517B2
(en)
|
2019-04-23 |
2024-11-12 |
Sangamo Therapeutics, Inc. |
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
BR112021024055A2
(pt)
|
2019-05-29 |
2022-02-08 |
Encoded Therapeutics Inc |
Composições e métodos para a regulação seletiva de gene
|
|
US20220273715A1
(en)
|
2019-07-25 |
2022-09-01 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
WO2021035054A1
(en)
|
2019-08-20 |
2021-02-25 |
Precision Biosciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20220324928A1
(en)
|
2019-10-02 |
2022-10-13 |
Sangamo Therapeutics, Inc. |
Zinc Finger Protein Transcription Factors for Repressing Alpha-Synuclein Expression
|
|
WO2021067864A1
(en)
|
2019-10-02 |
2021-04-08 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for treatment of prion disease
|
|
US20220411479A1
(en)
|
2019-10-30 |
2022-12-29 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
|
WO2021087358A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
|
CA3160096A1
(en)
|
2019-12-06 |
2021-06-10 |
Bruce J. Mccreedy Jr. |
Methods for cancer immunotherapy
|
|
TW202134288A
(zh)
|
2020-01-22 |
2021-09-16 |
美商聖加莫治療股份有限公司 |
用於抑制tau蛋白表現之鋅指蛋白轉錄因子
|
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
|
WO2021202513A1
(en)
|
2020-03-31 |
2021-10-07 |
Elo Life Systems |
Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
|
|
EP4146284A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur genetischen modifizierung von zellen zur freisetzung therapeutischer proteine
|
|
JP7750865B2
(ja)
|
2020-05-06 |
2025-10-07 |
セレクティス ソシエテ アノニム |
細胞ゲノムにおける外因性配列の標的化挿入のための方法
|
|
US20230183664A1
(en)
|
2020-05-11 |
2023-06-15 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
EP4150057A2
(de)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Verfahren zur herstellung von donor-batch zellen, die einen rekombinanten rezeptor exprimieren
|
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
|
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
|
EP4192875A1
(de)
|
2020-08-10 |
2023-06-14 |
Precision BioSciences, Inc. |
Antikörper und fragmente spezifisch für b-zellreifungsantigen und verwendungen davon
|
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
WO2022067122A1
(en)
|
2020-09-25 |
2022-03-31 |
Sangamo Therapeutics, Inc. |
Zinc finger fusion proteins for nucleobase editing
|
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
WO2022087527A1
(en)
|
2020-10-23 |
2022-04-28 |
Elo Life Systems, Inc. |
Methods for producing vanilla plants with improved flavor and agronomic production
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
MX2023005665A
(es)
|
2020-11-16 |
2023-08-01 |
Pig Improvement Co Uk Ltd |
Animales resistentes a la influenza a que tienen genes de anp32 editados.
|
|
WO2022165111A1
(en)
|
2021-01-28 |
2022-08-04 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
|
US20240141311A1
(en)
|
2021-04-22 |
2024-05-02 |
North Carolina State University |
Compositions and methods for generating male sterile plants
|
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
|
MX2024004812A
(es)
|
2021-10-19 |
2024-07-15 |
Prec Biosciences Inc |
Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat).
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023091910A1
(en)
|
2021-11-16 |
2023-05-25 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
US20250064032A1
(en)
|
2021-12-10 |
2025-02-27 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
IL313758A
(en)
|
2021-12-22 |
2024-08-01 |
Sangamo Therapeutics Inc |
Novel zinc finger fusion proteins for nuclear base editing
|
|
EP4460571A1
(de)
|
2022-01-05 |
2024-11-13 |
Vib Vzw |
Mittel und verfahren zur erhöhung der abiotischen stresstoleranz bei pflanzen
|
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
EP4658675A1
(de)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Verfahren zur nichtviralen herstellung von manipulierten immunzellen
|
|
KR20260010765A
(ko)
|
2023-04-14 |
2026-01-21 |
프리시젼 바이오사이언시스 인코포레이티드 |
근육-특이적 발현 카세트
|
|
WO2024216116A1
(en)
|
2023-04-14 |
2024-10-17 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
EP4713027A1
(de)
|
2023-05-16 |
2026-03-25 |
Omega Therapeutics, Inc. |
Verfahren und zusammensetzungen zur modulation der methylierung eines zielgens
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
TW202515898A
(zh)
|
2023-06-30 |
2025-04-16 |
日商武田藥品工業股份有限公司 |
Htt抑制物及其用途
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|